Table 2.
Characteristics of HIV Infected Participants By Metabolic Syndrome Status
| With MetS (N = 48) | Without MetS (N = 252) | p | |
|---|---|---|---|
| Gender | |||
| Female | 40 (83.3) | 152 (60.3) | 0.002 |
| Age, years mean (SD) | 43.2 ± 9.83 | 40.2 ± 9.42 | 0.05 |
| Age groups, years | |||
| 18–34 | 8 (16.7) | 69 (27.4) | 0.12 |
| 34–55 | 30 (62.5) | 157 (62.3) | 0.98 |
| >55 | 10 (20.8) | 26 (10.3) | 0.04 |
| Current tobacco users | 0 (0.0) | 10 (3.8) | 0.17 |
| Current alcohol drinking | 8 (16.7) | 53 (21.0) | 0.49 |
| Dyslipidemia | 43 (89.6) | 133 (52.8) | <0.001 |
| BMI ≥25 kg/m2 | 32 (66.7) | 93 (36.9) | <0.001 |
| Nadir CD4,a cells/mm3 | 251.9 (196.0) | 261.7 (185.9) | 0.79 |
| Peak viral load,b copies/mL | 195472.3 (185216.3) | 126071.9 (86873.08) | 0.82 |
| Length of HIV infection, years | 5.42 (4.9) | 5.3 (4.8) | 0.85 |
| ART duration, years | 4.7 (3.0) | 5.5 (3.3) | 0.2 |
| ART use | 25 (52.1) | 139 (55.2) | 0.70 |
| Type of ART | |||
| Lopinovir/ritonavir | 2 (8.0) | 9 (6.5) | 0.78 |
| Zidovudine | 11 (44.0) | 46 (33.1) | 0.29 |
| Lamuvidine | 24 (96.0) | 128 (92.1) | 0.49 |
| Tenofovir | 13 (52.0) | 96 (69.1) | 0.10 |
| Nevirapine | 13 (52.0) | 86 (61.9) | 0.35 |
| Efavirenz | 11 (44.0) | 40 (28.8) | 0.13 |
| Others | 2 (8.0) | 7 (5.0) | 0.55 |
Values are n (%) or mean ± SD.
a
N = 188.
b
N = 38.
ART, antiretroviral therapy; MetS, metabolic syndrome; BMI, body mass index; SD, standard deviation.